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Objective: Hyaluronic acid (HA) is currently used in Taiwan as intravesical instillation for the treatment of
interstitial cystitis/bladder pain syndrome (IC/BPS). This study investigated the therapeutic effects of HA
on IC/BPS in the Taiwanese population.
Materials and methods: Men and women aged 18 years with documented IC/BPS were initially treated
with four weekly intravesical HA instillations (treatment time, 1 month) and then with ﬁve monthly
instillations (total treatment time, 6 months). Clinical assessments included the evaluation of the Visual
Analog Scale (VAS) score of bladder pain, O'LearyeSant Symptom (OSS) score, IC Symptom Index (ICSI),
IC Problem Index (ICPI), functional bladder capacity (FBC), uroﬂowmetry parameters, and global response
assessment (GRA). Therapeutic effects were compared between responders (GRA increased  2 scales)
and nonresponders (GRA increased < 2). Multivariate linear analysis was used to determine predictive
factor for successful treatment.
Results: A total of 64 patients (3 men and 61 women) with mean age of 49.4 years (range, 20e79)
completed the study. Compared with the baseline data, VAS, ICSI, ICPI, OSS score, daytime frequency,
nocturia, and FBC all improved at 1 month or 6 months after starting HA treatment. Signiﬁcantly more
improvements in ICSI, ICPI, OSS score, VAS, and FBC were noted in the responders than in the non-
responders at 6 months of treatment. A low-grade glomerulation was the only predictor for successful
treatment response to intravesical HA treatment.
Conclusion: Intravesical HA administrations improved IC symptoms, decreased bladder pain, and
decreased frequency after four instillations, and decreased nocturia and increased bladder capacity after
completion of all nine instillations. Low-grade glomerulation predicts successful outcome.
Copyright © 2014, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic
bladder condition characterized by bladder pain, urination fre-
quency, and nocturia. Many different etiologies have been pro-
posed; however, none of these etiologies has been deﬁnitively
proven. Therefore, no single treatment has been reported to have a
long-term effect in eradicating symptoms of this mysterious
bladder disorder.1 IC/BPS is considered to result from long-standing
inﬂammation of the bladder. Histological analyses of the bladderBuddhist Tzu Chi General
70, Taiwan.
ciation. Published by Elsevier Taiwshow inﬁltrates of mast cells, eosinophilic leukocytes, and T lym-
phocytes, suggesting that the disease is mediated by the immune
system.2
Previous reports indicated that the urothelium plays a pivotal
role as a barrier between urine and its solutes and the underlying
bladder. Bladder surface mucus is a critical component of this
function.3e5 In patients with IC/BPS, disruption of the urothelial
barrier may initiate a cascade of events in the bladder, leading to
symptoms and disease. Speciﬁcally, urothelial dysfunction leads to
the migration of urinary solutes, in particular, potassium that de-
polarizes nerves and muscles and causes tissue injury.6,7 Conse-
quently, it is imperative to understand the biological effects by
which the urothelium changes its growth behavior and the
expression patterns of signal transduction molecules under these
effects.an LLC. Open access under CC BY-NC-ND license.
Table 1
Changes in values of urodynamic parameters at the 1- and 6-month evaluations.
Baseline 1 mo 6 mo p
VAS 4.25 ± 2.22 2.61 ± 1.87 2.33 ± 2.03 <0.001
ICSI 10.4 ± 3.73 7.41 ± 2.96 6.88 ± 3.11 <0.001
ICPI 9.63 ± 3.88 6.92 ± 3.62 5.94 ± 3.87 <0.001
OSS 20.0 ± 7.30 14.3 ± 6.15 12.8 ± 6.66 <0.001
FBC (mL) 158 ± 91.1 183 ± 88.2 214 ± 99.0 <0.001
Qmax (mL/s) 16.25 ± 9.56 16.87 ± 9.16 18.0 ± 10.5 0.346
Volume (mL) 227 ± 143 225 ± 137 233 ± 168 0.932
PVR (mL) 39.4 ± 48.4 36.6 ± 46.5 36.9 ± 57.6 0.920
Frequency/day 10.7 ± 5.46 8.13 ± 2.61 7.98 ± 2.88 <0.001
Nocturia/day 3.11 ± 1.61 2.44 ± 1.17 2.58 ± 1.32 0.001
FBC ¼ functional bladder capacity; ICPI ¼ Interstitial Cystitis Problem Index;
ICSI ¼ Interstitial Cystitis Symptom Index; OSS ¼ O'LearyeSant Symptom score;
PVR ¼ postvoid residual volume; Qmax ¼maximum ﬂow rate; VAS ¼ Visual Analog
Scale of pain.
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BPS involves an aberrant differentiation program in the bladder
urothelium that leads to altered synthesis of several proteoglycans,
cell adhesion and tight junction proteins, and bacterial defense
molecules (e.g., GP51).8 Therefore, replacement therapy with
glycosaminoglycan has been widely used for treatment of IC/BPS.
Hyaluronic acid (HA) is a nonsulfated mucopolysaccharide
component of the glycosaminoglycan layer and is present in the
subepithelial connective tissue to protect the bladder wall from
irritants in the urine.9,10 Intravesical treatment with this agent has
been investigated in IC/BPS patients. Morales et al10 treated 25 IC
patients with 40-mg HA weekly for 4 weeks and then monthly.
They reported an initial positive response rate of 56% at Week 4.
When the patients were evaluated at Week 12, the response rate
increased to 71%. This positive response rate was maintained until
Week 20, but decreased after Week 24.10 Recent studies also
conﬁrmed that intravesical instillation of HA can provide both
immediate and sustained relief of symptoms. Although various
treatment modalities of HA are available, including adding alka-
linized lidocaine,11 instillation of HA through electromotive drug
administration,12 or biweekly intravesical instillations,13 the ther-
apeutic efﬁcacy of all these modalities seems consistently
satisfactory.
HA has been used in treatments in Taiwan since 2007. At pre-
sent, HA is the most popular ﬁrst-line treatment for cystoscopy-
proven IC/BPS. This study investigated the therapeutic results and
the predictive factors of IC/BPS patients treated with intravesical
HA instillations in Taiwan.
2. Methods
This was a prospective clinical study. A total of 90 men and
women (age  18 years) with documented IC/BPS were selected for
HA treatment. All patients had the characteristics of IC/BPS and
were previously treated conservatively with heparin and/or
pentosan polysulfate and were refractory to treatment.14 All pa-
tients underwent urodynamic studies with 0.4 M potassium chlo-
ride (KCl) prior to cystoscopic hydrodistention. The patients
underwent cystoscopic hydrodistention at an intravesical pressure
of 80 cm of water andwere examined for glomerulations. The grade
of glomerulations was classiﬁed as 0e4, indicating none, mild,
moderate, and severe glomerulations, and as Hunner's lesions,
respectively.15 Patients with a cystometric bladder capacity of
>350 mL or without a positive KCl test during urodynamic testing
were not included in this study. Patients with urinary tract infec-
tion, stress urinary incontinence, chronic urinary retention, pelvic
organ prolapse, or neurogenic voiding dysfunction were also
excluded.
This study was approved by the Institutional Review Board and
Ethics Committee of the Buddhist Tzu Chi General Hospital, Hua-
lien, Taiwan and Tzu Chi University, Hualien, Taiwan. Each patient
was informed about the study rationale and procedures prior to the
treatment. Patients were also informed about the possible com-
plications associated with intravesical HA instillation, such as uri-
nary tract infection. Written informed consent was obtained from
every patient prior to participation.
The patients were treated with intravesical HA (40 mg in 50 mL
of solution; Cystistat, Mylan Teoranta, Galway, Ireland) instilled
weekly for 4 weeks followed by monthly instillation for 5 months.
The HA treatment was started 1 month after cystoscopic hydro-
distention. The patients did not receive any additional treatment.
Clinical assessments were performed at baseline,1 month (after the
4th HA instillation), and 6 months (after the 9th HA instillation). The
clinical assessments included symptom score, 3-day voiding diary,
and uroﬂowmetry. The symptoms at baseline and after HAtreatment were assessed using the O'LearyeSant Symptom (OSS)
score, IC Symptom Index (ICSI), IC Problem Index (ICPI),16,17 and 10-
point Pain Visual Analog Scale (VAS).18 In addition, the 3-day
voiding diary was used to assess functional bladder capacity
(FBC), daily frequency and nocturia, and uroﬂowmetry including
the maximum ﬂow rate (Qmax), voided volume, and postvoid re-
sidual volume at each time point.
Treatment efﬁcacy was analyzed based on the global response
assessment (GRA).19 Patients rated their bladder symptoms
compared with baseline on a 7-point, centered scale as follows:
markedly (þ3), moderately (þ2), or slightly improved (þ1), no
change (0), to slightly (1), moderately (2), and markedly worse
(3). Successful treatment outcomes were deﬁned as moderately
and markedly improved results after treatment.20,21 Patients who
responded to HA treatment were compared with patients who did
not respond to all parameters from baseline to 1 month and 6
months after starting HA treatment.
Continuous variables were expressed as means ± standard de-
viations, and categorical data were expressed as number and per-
centage. Statistical comparisons between the subgroups were
tested using Chi-square test for categorical variables, and the Wil-
coxon rank-sum test was used for continuous variables. The Wil-
coxon signed-rank test was used to evaluate the signiﬁcance of
differences at baseline and after treatment. Multivariate linear
analysis was used to determine the predictive factor for a successful
response to HA treatment at 6 months. All statistical assessments
were two sided and considered signiﬁcant at p < 0.05. Statistical
analyses were performed using SPSS version 15.0 statistical soft-
ware (SPSS, Inc., Chicago, IL, USA).
3. Results
A total of 90 patients were enrolled. After cystoscopic hydro-
distention, 26 patients withdrew from the study due to IC/BPS
symptom improvement after hydrodistention (n ¼ 8), severe
discomfort after the ﬁrst or second HA instillation (n¼ 10), or being
unable to continue HA instillations for 6 months (n ¼ 8). Finally, 64
patients completed the study and were available for ﬁnal analysis.
The patients (3 men and 61 women) ranged in age from 20 years to
79 years (mean, 49.4 years). Cystoscopic hydrodistention revealed
glomerulations of Grade 0 in three (4.7%) patients, Grade 1 in 26
(40.6%) patients, Grade 2 in 22 (34.4%) patients, Grade 3 in 10
(15.6%) patients, and Grade 4 in three (4.7%) patients. Hunner's
lesion was noted in ﬁve (8%) patients.
Overall, GRA improved by  2 scales in 31 patients (responders,
48.4%) and by < 2 scales in 33 patients (nonresponders, 51.6%).
Table 1 lists the results for all parameters measured at 1 month and
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showed signiﬁcant decrease at the 1- and 6-month assessments.
Urination frequency and nocturia also decreased at the 1- and 6-
month assessments. However, according to the GRA scale, moder-
ate and marked improvements were reported in 24 (38%) patients
and seven (11%) patients at the 1-month evaluation, and in 18 (28%)
patients and 13 (20%) patients at the 6-month evaluation, respec-
tively. At the 1-month evaluation, seven (11%) patients and 26 (41%)
patients reported no change or mild improvement; at the 6-month
evaluation, two (3%) patients reported worsened IC/BPS, ﬁve (8%)
patients had no change, and 26 (41%) patients had only mild
improvement. Overall, 31 (48%) patients were considered re-
sponders and 33 patients were nonresponders (52%); the mean age
was similar between the two groups of patients.
At 1 month after the treatment (4 treatments), responders
showed signiﬁcantly lower OSS score, ICSI, ICPI, VAS, daytime uri-
nation frequency, and higher GRA than did the nonresponders. At
the 6-month evaluation (9 treatments), in addition to OSS score,
ICSI, ICPI, VAS, frequency, and GRA, responders showed signiﬁ-
cantly greater FBC, Qmax, and fewer nocturia episodes than did the
nonresponders (Fig. 1). The changes in values of parameters from
baseline to the 6-month (last) measurement revealed signiﬁcantly
greater changes in OSS score, ICSI, ICPI, VAS, FBC, Qmax, and GRA in
the responders compared with the nonresponders (Table 2).
Although there were 33 nonresponders at 6 months, the changes in
OSS score, ICSI, ICPI, and daytime urination frequency from baseline
to the 1-month and 6-month evaluations were still statistically
signiﬁcant, suggesting a partial response in these patients.
Table 3 shows the statistical analysis between responders and
nonresponders. Only low-grade glomerulations predicted a suc-
cessful result. The other variables, such as presence of Hunner's
lesion, OSS score, VAS, maximal bladder capacity, and daily fre-
quency did not predict the treatment outcome.
During the HA treatment course, 12 episodes of urinary tract
infection developed among the 576 instillations (2.1%). No difﬁcult
urination, gross hematuria, or large postvoid residual volume wasFigure 1. Changes in O'LearyeSant Symptom (OSS) scores, Visual Analog Scale (VAS) pain s
(BL) to 1- and 6-month evaluations between responders and nonresponders. *p < 0.05.noted. No patient had any systemic adverse event. After the ﬁrst
course of HA treatment, eight (12%) patients remained in good
condition without further treatment, 12 (19%) patients continued
with the second course of HA treatment because of incomplete
symptom relief, 28 (44%) patients shifted to treatment with intra-
vesical botulinum toxin injection, and 16 (25%) patients received
oral pentosan polysulfate or other pain treatments.
4. Discussion
The study results conﬁrmed that intravesical HA instillation of
one course is an effective treatment for 48.4% of patients with IC/
BPS refractory to conventional therapy. Although only some of the
patients beneﬁted from the ﬁrst course of HA treatment, rates of
adverse events after HA instillation were low, indicating that HA
instillation is safe for IC/BPS treatment.
Treatment of IC/BPS is a considerable challenge to physicians.
Previous treatments included oral pentosan polysulfate,14 intra-
vesical injection of botulinum toxin A,21 intravesical instillation of
chondroitin,22 and prolonged hydrodistention,23 but none of these
provided long-term treatment success. The adverse events of
treatment, for example, the side effects of botulinum toxin-A in-
jection, which include voiding difﬁculty and painful urination,
should be taken into consideration.
Morales et al10 reported that 71% of IC/BPS patients had positive
responses to intravesical HA instillation. Intravesical HA instillation
resulted in higher drug concentrations than other treatments and
protected the bladdermucosa in patients with IC/BPS. However, not
many published studies had such consistent results. Our study
showed a lower success rate for one course of HA treatment con-
sisting of four weekly and ﬁve monthly instillations. Our patients
had chronic IC/BPS and were refractory to conventional therapy.
Moreover, the nonresponders had partial responses to the HA
treatments, and their IC symptom scores and daytime urination
frequency were signiﬁcantly improved at the 1- and 6-month as-
sessments. However, they did not report a GRA improvementcore, functional bladder capacity (FBC), and daytime urination frequency from baseline
Table 2
Changes in values of measured parameters between responders and nonresponders at 1 and 6 months after starting intravesical hyaluronic acid treatment.
Baseline 1 mo 6 mo p*
Age (y) Nonresponders (n ¼ 33)
Responders (n ¼ 31)
48.3 ± 12.8
50.5 ± 14.2
d d
OSS Nonresponders (n ¼ 33)
Responders (n ¼ 31)
21.0 ± 6.68
18.9 ± 7.88
16.8 ± 6.10**
11.7 ± 5.11**,***
19.7 ± 5.85**
8.39 ± 4.17**,***
0.001
ICSI Nonresponders (n ¼ 33)
Responders (n ¼ 31)
10.8 ± 3.46
9.87 ± 4.01
8.42 ± 3.07**
6.32 ± 2.45**,***
8.55 ± 3.01**
5.10 ± 2.09**,***
0.006
ICPI Nonresponders (n ¼ 33)
Responders (n ¼ 31)
10.2 ± 3.51
9.03 ± 4.21
8.36 ± 3.44**
5.39 ± 3.18**,***
8.42 ± 3.20**
3.29 ± 2.53**,***
< 0.001
VAS Nonresponders (n ¼ 33)
Responders (n ¼ 31)
4.09 ± 2.16
4.42 ± 2.31
3.09 ± 2.21**
2.10 ± 1.27**,***
3.33 ± 2.25
1.26 ± 1.00**,***
< 0.001
FBC (mL) Nonresponders (n ¼ 33)
Responders (n ¼ 31)
145 ± 86.7
172 ± 94.9
168 ± 84.4
200 ± 90.5**
168 ± 82.2
262 ± 93.3**,***
0.002
Frequency Nonresponders (n ¼ 33)
Responders (n ¼ 31)
11.1 ± 4.54
10.3 ± 6.35
8.94 ± 2.60**
7.26 ± 2.37**,***
9.12 ± 3.23**
6.77 ± 1.84**,***
0.213
Nocturia Nonresponders (n ¼ 33)
Responders (n ¼ 31)
3.30 ± 1.53
2.90 ± 1.70
2.61 ± 1.20**
2.26 ± 1.12**
2.97 ± 1.26
2.16 ± 1.27**,***
0.306
Qmax (mL/s) Nonresponders (n ¼ 33)
Responders (n ¼ 31)
15.8 ± 10.2
16.7 ± 8.93
15.3 ± 9.60
18.5 ± 8.50
15.0 ± 6.77
21.1 ± 12.7**,***
0.037
Volume (mL) Nonresponders (n ¼ 33)
Responders (n ¼ 31)
227 ± 150
226 ± 137
205 ± 121
247 ± 151
197 ± 175
271 ± 153
0.092
PVR (mL) Nonresponders (n ¼ 33)
Responders (n ¼ 31)
35.9 ± 38.0
43.1 ± 57.9
35.5 ± 42.8
37.7 ± 50.8
33.0 ± 52.8
40.9 ± 62.9
0.967
GRA Nonresponders (n ¼ 33)
Responders (n ¼ 31)
d
d
1.00 ± 0.66
2.00 ± 0.68***
0.73 ± 0.57
2.42 ± 0.50***
< 0.001
FBC ¼ functional bladder capacity; GRA ¼ global response assessment; ICPI ¼ Interstitial Cystitis Problem Index; ICSI ¼ Interstitial Cystitis Symptom Index;
OSS ¼ O'LearyeSant Symptom score; PVR ¼ postvoid residual volume; VAS ¼ Visual Analog Scale of pain.
* Changes in p values from baseline to 6 months between responders and nonresponders.
** Signiﬁcant difference in parameters between baseline and time points.
*** p < 0.05 between responders and nonresponders.
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FBC. It is possible that continued HA treatment courses would have
improved the success rates.
Studies of urothelial differentiation in IC/BPS patients demon-
strated that the acquisition of a transitional cell morphology
occurred in some regions of the IC-derived cell lines, suggesting a
subset of patients with IC/BPS might have failure of urothelial
cytodifferentiation, which could contribute to the disease and
bladder dysfunction.3 Yamada et al24 demonstrated an apoptotic
process in the microvascular endothelial cells of bladders with IC/
BPS. A recent study further revealed that urothelial homeostasis in
IC/BPS patients was signiﬁcantly impaired, and the abnormal uro-
thelial function was associated with chronic inﬂammation of the
bladder.25 Bladder pain and small bladder capacity likely resulted
from the defective urothelium and suburothelial inﬂammation.26
A recent prospective, nonrandomized study with 3-year follow
up of 20 IC/BPS patients revealed subjective continuing improve-
ment in pain and urination frequency; 11 (55%) patients treated
with intravesical HA chose to continue treatment for symptomatic
relief.27 Recent investigation also showed that intravesical HA
instillation successfully treated patients with IC/BPS or
cyclophosphamide-induced hemorrhagic cystitis.11e13,28 In the rat
immobilization stress model, mean bladdermast cell activation and
proinﬂammatory mediators were inhibited by HA.29 Using a
bladder urothelial cell line, the severity of inﬂammation based on
the release of interleukin-6 after adding tumor necrosis factor-
alpha was reduced after treatment with HA and chondroitin sul-
fate.30 These clinical results suggest that intravesical HA is poten-
tially effective for bladder inﬂammation in patients with IC/BPS.
The results of our study also show that higher grade glomer-
ulations signiﬁcantly lowered success rates compared to patients
with low-grade glomerulations. Glomerulation after cystoscopic
hydrodistention usually indicates a higher grade of inﬂammation in
the bladder wall. Chronic suburothelial inﬂammation could inhibit
normal basal cell proliferation and affect the apical urothelial
function.31,32 Chronic sensitization of afferent ﬁbers might involveboth peripheral and central mechanisms. A rise in bladder nerve
growth factor in the muscle or urothelium initiates signals that are
transported along the afferent nerves of the bladder to the dorsal
root ganglion or spinal cord.33 Treatment of urothelial dysfunction
cannot be solely based on replacement of defense glycoproteins of
the bladder urothelium. Based on these data, successful treatment
of IC/BPS should target several factors including urothelial defense
defects and suburothelial inﬂammation.
The response to HA treatment was signiﬁcant only after four
instillations and was evenmore signiﬁcant after completion of nine
instillations among responders. FBC increased in responders only at
6 months, but not at 1 month, suggesting that resolution of bladder
inﬂammation takes more than 1 month to achieve. Weekly HA
instillations in the 1st month successfully restored the barrier
function to urine solutes; therefore, the VAS and IC symptoms
improved. Nonetheless, the bladder inﬂammation could not be
resolved in such a short period of treatment. It is intriguing to note
that the three patients with high-grade glomerulations had re-
sponses at 1 month, but did not respond to the HA treatment at 6
months. It is possible that the bladder inﬂammation did not resolve
after the 1st month of intensive treatment; therefore, symptoms
relapsed when the instillation period increased from weekly to
monthly. Based on this observation, we postulate that patients with
high-grade glomerulations should be treated more intensely with
weekly HA instillation rather than following the conventional
treatment regimen.
The main limitation of this study is the lack of a control arm.
Because of ethical considerations, it is unconscionable to use a
placebo in this speciﬁc, vulnerable patient group. Nevertheless, we
demonstrated both subjective and objective improvements in
Taiwanese responders with IC/BPS, without serious side effects. In
addition, all patients had KCl test and urodynamic study performed
prior to cystoscopic hydrodistention, and these tests could have
caused worsening of their symptoms at baseline. However, the
baseline data were obtained 1 month after cystoscopic hydro-
distention and at the initiation of HA treatment, and the negative
Table 3
Comparison of the baseline demographics between responders and nonresponders
to HA treatment at 6 months.
Responders
(n ¼ 31)
Nonresponders
(n ¼ 33)
p
Sex 0.518
Male 2 (6.5) 1 (3)
Female 29 (93.5) 32 (97)
Age (y) 0.808
<30 1 (3.2) 2 (6.1)
30e50 16 (51.6) 18 (54.5)
>50 14 (45.2) 13 (39.4)
ICSI 9.9 ± 4.0 10.8 ± 3.5 0.314
ICPI 9.0 ± 4.2 10.1 ± 3.5 0.239
OSS 18.9 ± 7.9 21.0 ± 6.7 0.254
VAS 4.4 ± 2.3 4.1 ± 2.2 0.558
FBC (mL) 0.386
<100 10 (32.3) 14 (42.4)
100e250 12 (38.7) 14 (42.4)
>250 9 (29) 5 (15.2)
Frequency (per day) 0.395
8 5 (16.1) 3 (9.1)
>8 26 (83.9) 30 (90.9)
Qmax (mL/s) 0.719
<10 7 (22.6) 10 (30.3)
10e15 7 (22.6) 8 (24.2)
>15 17 (54.8) 15 (45.5)
PVR (mL) 0.487
<50 23 (74.2) 22 (66.7)
50e100 4 (12.9) 8 (24.2)
>100 4 (12.9) 3 (9.1)
Hunner's lesion 2 (6.5) 3 (9.1) 0.694
Nonulcer 29 (93.5) 30 (90.9)
MBC (mL) 0.316
<500 7 (22.6) 11 (33.3)
500e700 14 (45.2) 9 (27.3)
>700 10 (32.3) 13 (39.4)
Glomerulations 0.019
0 3 (9.7) 0
1 15 (48.4) 11 (33.3)
2 11 (35.5) 11 (33.3)
3 2 (6.5) 8 (24.2)
4 0 3 (9.1)
FBC ¼ functional bladder capacity; HA ¼ hyaluronic acid; ICPI ¼ Interstitial Cystitis
Problem Index; ICSI ¼ Interstitial Cystitis Symptom Index; MBC ¼maximal bladder
capacity; OSS ¼ O'LearyeSant Symptom score; PVR ¼ postvoid residual volume;
Qmax ¼ maximum ﬂow rate; VAS ¼ Visual Analog Scale of pain.
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that time.
5. Conclusion
Intravesical HA administration improved IC/BPS symptoms,
decreased bladder pain, and decreased urination frequency after
four instillations, and furthermore decreased nocturia and
increased bladder capacity after completion of nine instillations.
These results provide evidence supporting the hypothesis that HA
has therapeutic effects on patients with IC/BPS, especially those
with low-grade glomerulations.
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